Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anamorelin - Helsinn Therapeutics/Ono Pharmaceutical

Drug Profile

Anamorelin - Helsinn Therapeutics/Ono Pharmaceutical

Alternative Names: Adlumiz; Anamorelin HCl; Anamorelin hydrochloride; ONO-7643; RC-1291; RC-1291 HCl; ST-1291

Latest Information Update: 23 Apr 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Developer Helsinn Therapeutics; Ono Pharmaceutical
  • Class Appetite stimulants; Piperidines; Small molecules
  • Mechanism of Action Ghrelin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cachexia
  • Preregistration Anorexia
  • Phase II Fatigue

Most Recent Events

  • 21 Apr 2021 Launched for Cachexia in Japan (PO)
  • 14 Apr 2021 Helsinn Healthcare plans phase II trial for Cachexia and Anorexia (Prevention) in USA (PO, Tablet) in August 2021 (NCT04844970)
  • 22 Jan 2021 Registered for Cachexia in Japan (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top